celg assum coverag neutral post-bmi
messag assum coverag celg previous cover adnan
butt due re-align coverag updat estim
revenu forecast rate neutral buy previous sinc believ
risk/reward own stock post-bmi deal announc morn
balanc opportun upsid arbitrag potenti deal
close expect per compani ultim acquisit valu celg
determin bmi share price downsid risk exist transact get
reject sharehold
neutral cover seamu fernandez acquir celg surpris
announc celg announc enter definit merger
agreement acquir celg cash stock transact
propos deal celg sharehold receiv share cash
share celg celg sharehold also receiv one tradeabl conting valu right
cvr share celg certain pipelin mileston met end
cvr entitl holder receiv one-tim potenti payment cash
upon fda approv three ozanimod decemb liso-cel
decemb march board director
compani approv combin schedul close
deal current valu ex-cvr offer premium yesterday
close price celg attract sharehold view base
today close price share announc offer premium
yesterday close price celg upsid would view need
accret busi develop activ celg remain stand-alone entiti
account discount valu cvr probability-adjust basi
upsid celg sharehold would per celg share view
fairli close celg fair valu stand-alone compani includ probability-
adjust valu late stage pipelin asset fedratinib ozanimod luspatercept car-
product
transfer coverag neutral rate think risk/reward own stock
post-deal announc balanc opportun upsid arbitrag
potenti deal close also think downsid risk exist celg share close
today repres cvr discount propos acquisit
price take account bmi current share price discount time
propos deal close period discount rate contribut indic
addit cvr upsid arbitrag opportun could exist ultim
howev acquisit price determin bmi share price potenti deal
close residu risk exist deal wont close exampl reject
bmi sharehold context declin share price today vs
 although theoret possibl think less like anoth bidder
would emerg think would need all-cash similar valuat
among celg partner bgne buy like impact celg
acquisit close spoke bgne manag today note us bgne
right receiv right tislelizumab back celg
acquisit close addit termin fee would avoid potenti
intern depolar tislelizumab also market develop
opdivo importantli would minim impact oper aspect global
tislelizumab develop program sinc bgne alreadi oper run
on-going registr trial celg reimburs trial bgne
page analyst certif import disclosur
could potenti ask return chines right revlimid vidaza abraxan
/celg would topic negoti celg deal close
importantli bgne retain asian commerci infrastructur bigger
global compani
page analyst certif import disclosur
valu celg use discount cash flow analysi util wacc termin
growth rate valu commerci product select upcom pipelin asset use sum-of-
the-part method valu celg whole transfer coverag adnan butt
downgrad celg neutral buy follow confirm acquisit bristol-my squibb
upsid risk rate valuat celg includ celg obtain higher acquisit offer bmi
share price increas current close price given share-bas compon propos
acquisit potenti faster regulatori approv expect investor three ozanimod liso-
cel would increas valu cvr
downsid risk valuat includ propos acquisit close share price
declin current close price
page analyst certif import disclosur
amort acquir intang asset
acquisition-rel charg restructur
total cost expens
interest invest incom net
compani report guggenheim secur llc estim
page analyst certif import disclosur
celg margin growth
sg product sale
 revenu
cog product sale
soe sg
compani report guggenheim secur llc estim
page analyst certif import disclosur
cash equival
properti plant equip net
short-term borrow current portion long-term debt
accru expens current liabil
long-term debt net discount
compani report guggenheim secur llc estim
page analyst certif import disclosur
chang
flow oper
account payabl oper liabil
flow invest activ
increase/decreas secur intang fin asset
flow financ activ
payment treasuri share
net payment/proce show term borrow
proce long term debt issu
princip repay current portion long-term debt
effect currenc rate chang cash cash equival
compani report guggenheim secur llc estim
page analyst certif import disclosur
